Upstream Bio (UPB) Net Income towards Common Stockholders (2023 - 2026)

Upstream Bio's Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$40.6 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 48.74% year-over-year to -$40.6 million; the TTM figure through Mar 2026 stood at -$156.7 million (down 74.82% YoY), while the FY2025 annual figure was -$143.4 million, down 87.76% from the prior year.
• Net Income towards Common Stockholders was -$40.6 million for Q1 2026 at Upstream Bio, up from -$42.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$6.3 million in Q3 2023 to a low of -$42.5 million in Q4 2025.
• Historically, Net Income towards Common Stockholders has averaged -$25.6 million across 4 years, with a median of -$21.8 million in 2024.
• Biggest YoY gain for Net Income towards Common Stockholders was 45.42% in 2024; the steepest drop was 236.37% in 2024.
• A 4-year view of Net Income towards Common Stockholders shows it stood at -$15.0 million in 2023, then sank by 45.42% to -$21.8 million in 2024, then sank by 94.86% to -$42.5 million in 2025, then grew by 4.47% to -$40.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$40.6 million (Q1 2026), -$42.5 million (Q4 2025), and -$33.7 million (Q3 2025), per Business Quant data.